Ginkgo Bioworks Holdings, Inc. (DNA)

NYSE: DNA · USD

$13.3

+2.05 (+18.2%)· Recorded snapshot

Market cap	897M
Revenue (ttm)	132.4M
Net income (ttm)	-290.8M
EPS (ttm)	-$4.96
Shares out	67.3M
Volume	3,499,983
Beta	1.79

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 132.4M
Net income (ttm): -290.8M
EPS (ttm): -$4.96
Market cap: 897M

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
EXAS	Exact Sciences Corp	—	—	—	—	—	—	نگه‌داری

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-28 19:55 UTC

Forward P/En/a

P25 n/aP50 n/aP75 n/a

Trailing P/En/a

P25 n/aP50 n/aP75 n/a

ROE-59.9

P25 n/aP50 n/aP75 n/a

ROIC-19.9

P25 n/aP50 n/aP75 n/a

Benchmarks · 1M

All DNA indicators

Market & fundamental data

Available fields

208

Groups with data

Currency

USD

Showing 208 of 208 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	USD
CIK code	0001830214
Company name	Ginkgo Bioworks Holdings, Inc.
Country	United States
Country code	US
CUSIP number	37611X209
Earnings date	2026-11-09
Earnings time	amc
Employees	485
Employees change	-349
Employees growth	-41.85%
Enterprise value	$998.9M
Exchange	NYSE
Financial currency	USD
Financial report date	2026-06-30
First seen	2026-05-09
Fiscal year end	December
Founded	2008
In index	RUSSELL2000
Industry	Biotechnology
Is primary listing	Yes
Is SPAC	No
ISIN number	US37611X2099
Last 10-K release date	2026-02-26
Last earnings date	2026-08-05
Last refreshed	2026-10-28
Last stock split date	2024-08-20
Last stock split type	Reverse
Market cap	$897M
Market cap category	Small-Cap
Next earnings date	2026-11-09
Options	Yes
Price	$13.32
Price currency	USD
Sector	Healthcare
SIC code	2836
Stock price date	2026-10-28
Symbol	DNA
U.S. state	Massachusetts
Website	https://www.ginkgo.bio

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings yield	-37.26%
EV/Sales	7.47x
FCF / EV yield	-17.67%
FCF yield	-19.69%
Forward EV/Sales	10.7x
Forward P/S	9.6x
P/B ratio	1.71x
P/S ratio	6.7x
Price / tangible book value	2.36x
Sector forward P/E	23.56x
Sector P/E	50.08x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT margin	-224.33%
EBITDA margin	-197.57%
Gross margin	68.04%
Operating margin	-224.33%
Pretax margin	-234.28%
Profit margin	-219.6%
Profit per employee	$-599,594
Revenue per employee	$273,033
ROA	-16.72%
ROA (5Y)	-39.94%
ROCE	-32.38%
ROE	-59.94%
ROE (5Y)	-96.45%
ROIC	-19.9%
SBC / revenue	51.96%
Tax / revenue	-0.45%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth quarters	1
EPS growth years	4
Gross profit growth	-49.71%
Gross profit growth (Q)	-45.38%
Gross profit growth 3Y	-26.89%
Gross profit growth 5Y	3.28%
Net income growth quarters	3
Net income growth years	3
Revenue growth	-37.02%
Revenue growth (Q)	-48.5%
Revenue growth (QoQ)	3.5%
Revenue growth 3Y	-25.94%
Revenue growth 5Y	-0.1%
Revenue growth years	0

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Capital expenditures	$-4.6M
Depreciation and amortization	$35.4M
EBIT	$-297.1M
EBITDA	$-261.6M
EPS	$-4.96
FCF per share	$-2.60
Financing cash flow	$34.6M
Free cash flow	$-174.8M
Free cash flow minus SBC	$-243.6M
Gross profit	$90.1M
Income taxes	$-594,000
Investing cash flow	$56.5M
Net borrowing	$-68,000
Net cash flow	$-79.3M
Net income	$-290.8M
Operating cash flow minus SBC	$-239M
Operating income	$-297.1M
Revenue	$132.4M
Stock-based compensation	$68.8M

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Altman Z-Score	-8.82
Book value per share	$6.60
Debt / equity	0.96
Long-term assets	$657.5M
Long-term liabilities	$497M
Net cash (debt)	$-102M
Net cash / market cap	-11.49%
Net debt / equity	0.24
Piotroski F-Score	1
Property, plant and equipment	$504.8M
Shareholders' equity	$420.3M
Tangible book value	$375.9M
Tangible book value per share	$5.90
Total assets	$990M
Total cash	$302.2M
Total debt	$404.1M
Total liabilities	$569.8M
WACC	9.7%

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Asset turnover	0.12
Current assets	$332.5M
Current liabilities	$72.7M
Current ratio	4.57
Net working capital	$-42.4M
Quick ratio	4.33
Working capital	$259.8M
Working capital turnover	0.39

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	-8.92%
Dividend yield	0%
Shareholder yield	-8.92%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
150-day SMA	$8.62
1D price change	18.19%
1M price change	26.74%
1M total return	26.74%
1W price change	37.02%
1W total return	37.02%
1Y price change	0.9%
1Y return CAGR	0.9%
1Y total return	0.9%
20-day SMA	$11.48
200-day SMA	$8.56
3M price change	81.34%
3M total return	81.34%
3Y price change	-74.98%
3Y return CAGR	-36.98%
3Y total return	-74.98%
50-day SMA	$9.37
50-day SMA vs 200-day SMA	50over200
52-week high	$18.22
52-week high date	2026-10-06
52-week low	$5.37
52-week low date	2026-03-30
5Y price change	-97.64%
5Y return CAGR	-52.75%
5Y total return	-97.64%
6M price change	72.76%
6M total return	72.76%
All-time high	$634.56
All-time high date	2021-11-09
All-time low	$5.00
All-time low date	2025-04-04
Average true range (ATR)	$1.26
Average volume	3.4M
Beta (1Y)	2.97
Beta (2Y)	3.16
Beta (5Y)	1.79
Change from 52-week high	-26.89%
Change from 52-week low	148.05%
Change from all-time high	-97.87%
Change from all-time low	170.2%
Change from open	15.83%
Day's gap	2.04%
Dollar volume	$46.6M
High price	$13.66
Low price	$11.49
Monthly RSI	41.22
Open price	$11.50
Position in 52-week range	84.33%
Premarket change	-1.42%
Premarket close	$11.27
Premarket price	$11.11
Premarket volume	19.3K
Previous close	$11.27
Price vs 150-day SMA	56.67%
Price vs 20-day SMA	17.68%
Price vs 200-day SMA	57.75%
Price vs 50-day SMA	44.26%
Relative volume	1.02
RSI	65.21
Sharpe ratio	0.48
Sharpe ratio (3Y)	-0
Sharpe ratio (5Y)	-0.28
Sortino ratio	0.78
Sortino ratio (3Y)	0.05
Sortino ratio (5Y)	-0.35
Volume	3.5M
Weekly RSI	63.42
YTD price change	62.58%
YTD total return	62.58%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	50M
Float percentage	74.3%
Shares change (QoQ)	4.25%
Shares change (YoY)	8.92%
Shares held by insiders	14.73%
Shares held by institutions	53.66%
Shares outstanding	67.3M
Short % of float	14.62%
Short % of shares	10.86%
Short ratio	3.9 days

Deeper analysis on DNA

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this DNA report

Is a complete DNA research report available?

No complete published report is available for Ginkgo Bioworks Holdings, Inc. (DNA) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

Ginkgo Bioworks Holdings, Inc. (DNA)

Price

Financial snapshot

Fair-value bridge

Latest news · DNA

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All DNA indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on DNA

Frequently asked questions